Cerebral stroke is a concern with high morbidity and mortality rates globally. Early
diagnosis and assessment are important in treatment of acute ischemic stroke (AIS).
In recent years, the field of neuroradiology has rapidly changed and advanced with
new technology and innovations. The utility of different imaging techniques has been
reported in structural and functional evaluation of the brain.[1-3] Imaging evaluation almost covers
the whole evolution process of cerebral stroke, from early diagnosis to treatment
strategy decisions, and from predicting the prognosis to post-stroke assessment.
Imaging of the infarction core and ischemic penumbra
The most important goal for treatment of AIS is to restore blood flow to the ischemic
penumbra for the remaining salvageable tissue as soon as possible. Therefore, early
and accurate identification of the infarct core and ischemic penumbra is crucial for
treatment of AIS and clinical outcome. Non-enhanced computed tomographic (CT)
imaging is regularly used to exclude hemorrhage and other diseases. Certain signs on
plain CT images may indicate early changes in AIS, such as obscuration of the
lentiform nucleus/insular ribbon, hyperdense arterial sign, loss of the gray–white
matter interface, and swollen cerebral tissue. Baseline CT showing a large area of
hypoattenuation is considered as an indicator of poor outcome. However, there is
insufficient evidence to identify the threshold of acute hypoattenuation that
affects treatment responses as shown by CT.[4] Diffusion-weighted magnetic resonance imaging (MRI) is the most useful method
for detecting hyperacute ischemia. MRI can detect abnormal cytotoxic edema in the
early stage and shows clear discrimination between ischemic lesions and normal brain
tissue. The abnormal extent and patterns of baseline diffusion-weighted imaging
(DWI) might help to predict the clinical outcome of patients with stroke.[5,6]Hypoperfusion abnormalities can be accurately measured using CT perfusion and
perfusion-weighted imaging (PWI). However, validation of the perfusion threshold for
the penumbra has not been established. An option is to identify the mismatch between
the infarct core and hypoperfusion tissue. Variable mismatch models have been
established and investigated. The most widely applicable model is DWI-PWI mismatch,
but this model might not optimally define the penumbra.[7,8] Particular advances include
application of arterial spin labeling (ASL) to obtain perfusion information, and
this method spares patients from administration of contrast medium. ASL can
delineate large perfusion deficits and perfusion-diffusion mismatches in
correspondence with dynamic susceptibility contrast.[9] Susceptibility-weighted imaging-diffusion mismatch was investigated in
several studies with discrepant results.[10,11] CT mismatch models that
included different parameters (e.g., computed tomography angiography [CTA] source
images-computed tomography perfusion [CTP] mismatch/CTP cerebral blood volume-mean
transit time [CBV-MTT] mismatch/CTP cerebral blood flow-maximum of tissue residual
function) were also compared with magnetic resonance (MR) models and the
correlations were investigated in relation to clinical outcome.[12-14] A clinical-imaging mismatch
model was also applied to estimate the amount of tissue impairment. Several studies
showed that clinical National Institutes of Health Stroke Scale scores and Alberta
Stroke Program Early CT Score on DWI mismatch might be associated with neurological
outcome in patients treated with intravenous tissue plasminogen activator.[15,16] The
clinical-CTP CBV mismatch shows lower specificity compared with the
diffusion/perfusion-weighted concept.[17] Further research is required to verify whether a clinical-imaging mismatch is
useful in managing acute stroke.Patients with AIS should receive intravenous tissue-type plasminogen activator
treatment within 3 or 4.5 hours of symptom onset. Imaging techniques that provide
more pathophysiological information might help to extend this time window and enable
selection of the most appropriate candidates for early treatment. Many large-scale,
multicenter trials have investigated the use of advanced imaging techniques for
evaluating thrombolytic therapy for patients with an extended time window.[18-20] The current problem for these
mismatch models is a lack of validation. Some randomized, clinical trials (RCTs)
that used advanced, multimodal imaging (CTP, diffusion-perfusion mismatch) for
thrombolysis treatment failed to demonstrate clinical efficacy in
patients.[21,22] Two recent RCTs used imaging criteria to select patients
with > 6 hours from onset for mechanical thrombectomy. One trial was the DEFUSE 3
trial, which used the perfusion-core volume ratio and initial infarct size as
imaging criteria.[23] The Clinical Mismatch in the Triage of Wake Up and Late Presenting Strokes
Undergoing Neurointervention With Trevo (DAWN) trial used clinical-imaging mismatch
(a combination of National Institutes of Health Stroke Scale scores and imaging
findings on CTP or DW-MRI) as an eligibility criterion.[24] Both studies showed benefit in functional outcome at 90 days in the treatment
group. Future RCTs may demonstrate additional imaging eligibility criteria to be
used in selection of patients who can benefit from mechanical thrombectomy. However,
more precise definitions of imaging mismatch with validation of measures for the
ischemic core and exclusion of benign oligemia need to be investigated.
Arterial stenosis, occlusion, and thrombus imaging
Severe stenosis and occlusion of large cerebral arteries are related to patients’
treatment and prognosis. MR angiography or CTA is important in multimodal imaging
protocols to assess arterial stenosis or occlusion. A thrombus or clot usually
blocks the proximal part of the cerebral artery and is a major concern in treating
acute stroke thrombolysis or mechanical thrombectomy. Indirect confirmation of
thrombi can be performed through observing obstruction of arterial blood flow, while
directly visualizing the thrombus may be more useful. Imaging manifestations and the
pathological component of obstructive thrombosis are closely related to the
therapeutic response and clinical prognosis.Plain CT “dense artery” sign may indicate a thrombus, but its sensitivity is poor.
Susceptibility-weighted MRI along with standard MRI may be more useful for detecting
thrombus. Susceptibility-weighted imaging is superior to fluid-attenuation
inversion-recovery MRI and CT in detecting cerebral thromboemboli.[25] Molecular MRI and positron emission tomography-based thrombus imaging in
animals have shown optimal results that may require further investigation in human
studies.[26,27]
Imaging assessment of the collateral circulation
The collateral circulation plays a crucial role in the pathophysiology of ischemicstroke, and is closely related to the treatment response and the patient’s prognosis.[28] The presence of good collateral circulation may help sustain the penumbral
area and enhance the rates of successful reperfusion.[29] The first grade of collateral circulation (circle of Willis) can be
visualized using CTA, MR angiography, and digital subtraction angiography. The
secondary collateral circulation (leptomeningeal arterial supply) could only be
visualized and assessed by conventional angiography in previous years. However, with
development of neuroimaging techniques, understanding of the collateral circulation
has been greatly enhanced in recent years.[30] Multiphase or dynamic CTA is an independent predictor of radiological and
clinical outcomes of patients with AIS. CTA provides information of arterial,
capillary, and venous phases of cerebral arteries, and it has a higher accuracy
compared with single-phase CTA for assessment of collaterals.[31] CTP source images can also be analyzed at different points of time around the
ischemic region to assess the collateral circulation status. In recent years, the
presence of arteries via artifacts (arterial transit artifact) on ASL cerebral blood
flow images and territory ASL has been applied to evaluate the collateral
circulation.[32,33] Despite the invasive nature of digital subtraction angiography,
it is the gold standard and the best method for assessing different grades of the
collateral circulation. Noninvasive methods, including CTA, MR angiography, and ASL
imaging, can also provide direct or indirect evaluation of first and second grade
collaterals. Acute stroke imaging protocols should include one of these noninvasive
methods for assessing the collateral circulation, either based on CT or MR
techniques.
Post-stroke imaging assessment
After vascular recanalization, imaging needs to be performed to observe progression
of the lesion, including the condition of recanalization, reperfusion status, and
hemorrhagic transformation. Although hyperperfusion after vascular recanalization is
rare, it requires a lot of attention. Major hyperperfusion in an ischemic region
often leads to hemorrhagic transformation or worsening of the disease, known as
reperfusion injury. Perfusion imaging can provide related information for
hyperperfusion after treatment. The Modified Thrombolysis in Cerebral Infarction
score is a current assessment tool with proven value in reflecting the reperfusion
status and predicting clinical outcomes.[34]Although imaging-guided treatment for AIS still requires more clinical evidence,
multimodal imaging plays a major role in diagnosis and treatment of stroke. Advanced
imaging modalities may help perform a paradigm shift in stroke imaging from simply
providing diagnosis to providing comprehensive assessment for patients, with the
final goal of establishing individualized medical treatment. This scope is expected
to be the future direction in this field and be fulfilled with application of
advanced imaging techniques.
Declaration of conflicting interest
The authors declare that there is no conflict of interest.
Authors: Greg Zaharchuk; Huy M Do; Michael P Marks; Jarrett Rosenberg; Michael E Moseley; Gary K Steinberg Journal: Stroke Date: 2011-07-28 Impact factor: 7.914
Authors: Anna Kruetzelmann; Martin Köhrmann; Jan Sobesky; Bastian Cheng; Michael Rosenkranz; Joachim Röther; Peter D Schellinger; Peter Ringleb; Christian Gerloff; Jens Fiehler; Götz Thomalla Journal: Stroke Date: 2011-03-17 Impact factor: 7.914
Authors: D Byrne; G Sugrue; E Stanley; J P Walsh; S Murphy; E C Kavanagh; P J MacMahon Journal: AJNR Am J Neuroradiol Date: 2017-08-10 Impact factor: 3.825
Authors: Pablo García-Bermejo; Ana I Calleja; Santiago Pérez-Fernández; Elisa Cortijo; José M del Monte; Miguel García-Porrero; M Fe Muñoz; Rosario Fernández-Herranz; Juan F Arenillas Journal: Cerebrovasc Dis Date: 2012-06-29 Impact factor: 2.762
Authors: Werner Hacke; Anthony J Furlan; Yasir Al-Rawi; Antoni Davalos; Jochen B Fiebach; Franz Gruber; Markku Kaste; Leslie J Lipka; Salvador Pedraza; Peter A Ringleb; Howard A Rowley; Dietmar Schneider; Lee H Schwamm; Joaquin Serena Leal; Mariola Söhngen; Phil A Teal; Karin Wilhelm-Ogunbiyi; Max Wintermark; Steven Warach Journal: Lancet Neurol Date: 2008-12-25 Impact factor: 44.182